Biomea Fusion, Inc.

Contributing Author

Recent Articles by Biomea Fusion, Inc.

Jun-13	Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025 BMEA -9.58% GlobeNewswire
May-14	Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia BMEA GlobeNewswire
May-05	Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights BMEA GlobeNewswire